
KLDO
Healthcare · Biotechnology · $4,262 market cap
$0.00010.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2022
EPS trend, 90 days to now · 30-day revisions 0 up, 1 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 10, 2022 | Time not confirmed | -0.25 | 0.00 | +100.0% |
| Apr 1, 2022 | Before the open | -0.58 | -0.48 | +17.2% |
| Mar 29, 2022 | Time not confirmed | -0.59 | -0.48 | +18.6% |
| Nov 1, 2021 | Before the open | -0.54 | -0.54 | 0.0% |
| Aug 11, 2021 | Before the open | -0.58 | -0.56 | +3.4% |
| May 4, 2021 | Before the open | -0.60 | -0.58 | +3.3% |
| Mar 3, 2021 | Before the open | -0.40 | -0.56 | -40.0% |
| Nov 2, 2020 | Before the open | -0.63 | -0.65 | -3.2% |
| Aug 4, 2020 | Before the open | -0.59 | -0.59 | 0.0% |
| May 14, 2020 | Before the open | -0.64 | -0.64 | 0.0% |
| Mar 2, 2020 | Before the open | -0.34 | -0.65 | -91.2% |
| Oct 30, 2019 | After the close | -0.90 | -0.74 | +17.8% |
| Aug 1, 2019 | Before the open | -1.00 | -0.83 |
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease,…
| +17.0% |
| May 2, 2019 | Before the open | -0.74 | -0.68 | +8.1% |
| Mar 1, 2019 | After the close | 0.00 | -0.23 | — |
| Sep 25, 2018 | Time not confirmed | — | -0.79 | — |